Drug intelligence / Profile preview

ro5027838

Development stage: Phase 2
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO5027838 is an oral small molecule drug developed by Hoffmann-La Roche for the treatment of Type 2 Diabetes Mellitus. It was investigated in phase 2 clinical trials as a potential therapy to improve glycemic control in patients with type 2 diabetes who were already on stable doses of metformin. The precise mechanism of action remains unknown and no novel mechanism has been reported. The drug was not approved for any indication and there are no known adverse events associated with its use from available data[1][4][7].

Other names: 68Tnb87D2Z5,8-Methanocinnoline 3-cyclopropyl-5,6,7,8-tetrahydro-8,9,9-trimethyl (5R,8S)(1S,8R)-

Targets

HSD11B2 (11β-HSD2)

Beyond the preview

Go deeper on ro5027838.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ro5027838.

Explore the full profile